Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus oral etoposide for platinum-resistant or platinum-refractory ovarian cancer
ChiCTR1800019970Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib and etoposide in ovarian cancer (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1800019970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019970.